Literature DB >> 26648533

Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: estimating the burden on health care.

R S Go1,2, K M Swanson2, L R Sangaralingham2, E B Habermann2, N D Shah2,3.   

Abstract

Mesh：

Year:  2015        PMID： 26648533     DOI： 10.1038/leu.2015.336

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Authors:  Elin Edda Sigurdardottir; Ingemar Turesson; Sigrun Helga Lund; Ebba K Lindqvist; Sham Mailankody; Neha Korde; Magnus Björkholm; Ola Landgren; Sigurdur Y Kristinsson
Journal:  JAMA Oncol       Date:  2015-05       Impact factor: 31.777

3.  Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

Authors:  Haijun Wang; Yiming Chen; Fanglin Li; Kay Delasalle; Jialei Wang; Raymond Alexanian; Larry Kwak; Luis Rustveld; Xianglin L Du; Michael Wang
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

4.  Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.

Authors:  Ronald S Go; Jacob D Gundrum; Joan M Neuner
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-28

5.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study.

Authors:  Adam J Waxman; Pamela J Mink; Susan S Devesa; William F Anderson; Brendan M Weiss; Sigurdur Y Kristinsson; Katherine A McGlynn; Ola Landgren
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

6.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.

Authors:  Terry M Therneau; Robert A Kyle; L Joseph Melton; Dirk R Larson; Joanne T Benson; Colin L Colby; Angela Dispenzieri; Shaji Kumar; Jerry A Katzmann; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2012-08-07       Impact factor: 7.616

8.  Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.

Authors:  Ola Landgren; Jerry A Katzmann; Ann W Hsing; Ruth M Pfeiffer; Robert A Kyle; Edward D Yeboah; Richard B Biritwum; Yao Tettey; Andrew A Adjei; Dirk R Larson; Angela Dispenzieri; L Joseph Melton; Lynn R Goldin; Mary L McMaster; Neil E Caporaso; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

9.  Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.

Authors:  Masako Iwanaga; Masuko Tagawa; Kunihiro Tsukasaki; Shimera Kamihira; Masao Tomonaga
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

Review 10.  Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.

Authors:  Charlene M McShane; Liam J Murray; Ola Landgren; Michael A O'Rorke; Neha Korde; Andrew T Kunzmann; Mohammad Roshidi Ismail; Lesley A Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01-22       Impact factor: 4.254
View more
  8 in total

Review 1.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

2.  Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA.

Authors:  Ronald S Go; Herbert C Heien; Lindsey R Sangaralingham; Elizabeth B Habermann; Nilay D Shah
Journal:  Haematologica       Date:  2017-12-21       Impact factor: 9.941

3.  Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.

Authors:  Shaji Kumar; Dirk R Larson; Angela Dispenzieri; Terry M Therneau; David L Murray; P Leif Bergsagel; Robert A Kyle; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2019-05-17       Impact factor: 11.037

4.  Methods for reducing delays in the diagnosis of multiple myeloma.

Authors:  Constantinos Koshiaris
Journal:  Int J Hematol Oncol       Date:  2019-02-26

5.  A Single-Center Retrospective Study to Investigate the Follow-Up of Patients with Monoclonal Proteinemia by Community Physicians in the UK.

Authors:  Indra Ramasamy
Journal:  J Blood Med       Date:  2020-06-11

Review 6.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

7.  Monoclonal Gammopathy of Undetermined Significance: Follow-up Patterns in the United States and Concordance With Clinical Practice Guidelines.

Authors:  Ronald S Go; Herbert C Heien; Lindsey R Sangaralingham; Elizabeth B Habermann; Nilay D Shah
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2017-08-02

8.  Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma.

Authors:  Imad Maatouk; Susanne He; Manuela Hummel; Stefan Hemmer; Michaela Hillengass; Hartmut Goldschmidt; Mechthild Hartmann; Wolfgang Herzog; Jens Hillengass
Journal:  Blood Cancer J       Date:  2019-01-21       Impact factor: 11.037
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.